NICE, France--(BUSINESS WIRE)--April 4, 2006--Oscient Pharmaceuticals Corporation's (Nasdaq: OSCI - News) lead product, FACTIVE® (gemifloxacin mesylate) tablets, is the subject of two poster presentations at the 16th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). One of the leading conferences in infectious diseases in Europe, ECCMID attracts over 5,000 scientists, healthcare providers and industry representatives to address important medical issues and trends.
